Mauna Kea Technologies Reports 2026 Mid-Year Financial Results

Mauna Kea Technologies has announced its half-year results for 2026, highlighting a 37% increase in product and service revenues, totaling €3.2 million. This growth was driven by the success of CellTolerance® in Europe and new markets such as the UAE and Australia. The company's gross margin rose to 65%, a 2-point improvement from the previous year.

Operating expenses slightly decreased, with R&D and general administration costs seeing a reduction. The operating loss amounted to €4.2 million, mainly due to the absence of previous licensing revenues, but the financial outlook has been extended to the end of 2027, backed by shareholder Vester Finance.

Internationally, CellTolerance expanded significantly, with regulatory clearances in new regions enhancing market reach. In the U.S., a new Clinical Associates team has been established to boost Cellvizio usage, signaling potential future growth. The net loss reported was €4.8 million, a marginal increase from the previous year.